Wyeth’s farm team
Wyeth's "most interesting" developmental project "from a scientific point of view" is the anti-GDF8 antibody MYO-029, in Phase I as a potential treatment for type II diabetes and for wasting diseases, CEO Robert Essner told the J.P. Morgan H&Q conference Jan. 7 in San Francisco. The antibody targets myostatin, which is believed to decrease muscle mass and increase fat and glucose levels in the blood. Essner showed a picture of the Belgian Blue Bull, a species that naturally lacks GDF8; it is "an animal that is massive, is muscled, is low fat, but otherwise lives a very healthy normal lifecycle." If the compound advances in development, it could give Wyeth a new barnyard symbol to supplant the pregnant mares that provide the raw material for the company's flagship conjugated estrogens line...
You may also be interested in...
Splitting Colfax into separate fabrication technology and specialty medical technology businesses will help both sides of the business grow, CEO Matthew Trerotola said recently.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.
Use of per- and polyfluoroalkyl substances in cosmetic products appears to be declining, based on voluntary industry registrations with the US Food and Drug Administration. In any event, NGOs are gunning for PFAS' elimination, and the FDA says available data have yet to give a complete safety picture for PFAS used intentionally in cosmetics or present as impurities.